We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.58B
AUM Growth
+$403M
Cap. Flow
+$220M
Cap. Flow %
13.93%
Top 10 Hldgs %
32.67%
Holding
149
New
11
Increased
79
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.7M
3
PACB icon
Pacific Biosciences
PACB
+$11M
4
MDT icon
Medtronic
MDT
+$8.74M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$8.4M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.7M
2
BHC icon
Bausch Health
BHC
+$3.02M
3
AMGN icon
Amgen
AMGN
+$2.16M
4
GILD icon
Gilead Sciences
GILD
+$1.72M
5
KTWO
K2M Group Holdings, Inc
KTWO
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 93.18%
2 Industrials 1.09%
3 Technology 0.34%
4 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
126
PTC Therapeutics
PTCT
$6.52B
$1.06M 0.07%
+22,500
New +$931K
XLRN
127
DELISTED
Acceleron Pharma
XLRN
$927K 0.06%
+16,200
New +$796K
MRK icon
128
Merck
MRK
$315B
$887K 0.06%
13,100
– –
VYGR icon
129
Voyager Therapeutics
VYGR
$192M
$822K 0.05%
43,422
+26,500
+157% +$508K
ADAP
130
DELISTED
Adaptimmune Therapeutics
ADAP
$794K 0.05%
58,535
-1,400
-2% -$14.7K
QURE icon
131
uniQure
QURE
$2.77B
$724K 0.05%
19,900
-300
-1% -$11.2K
PTLA
132
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$710K 0.05%
26,650
-14,850
-36% -$485K
VAR
133
DELISTED
Varian Medical Systems, Inc.
VAR
$705K 0.04%
6,300
– –
PINC
134
DELISTED
Premier
PINC
$691K 0.04%
+15,100
New +$609K
CVS icon
135
CVS Health
CVS
$137B
$630K 0.04%
8,000
– –
HCSG icon
136
Healthcare Services Group
HCSG
$1.74B
$609K 0.04%
15,000
– –
NTLA icon
137
Intellia Therapeutics
NTLA
$1.59B
$470K 0.03%
16,434
-300
-2% -$8.73K
IOVA icon
138
Iovance Biotherapeutics
IOVA
$2.23B
$281K 0.02%
+25,000
New +$355K
ALKS icon
139
Alkermes
ALKS
$8.79B
– –
-32,650
Closed -$1.34M
BHC icon
140
Bausch Health
BHC
$1.8B
– –
-130,000
Closed -$3.02M
CAH icon
141
Cardinal Health
CAH
$53.5B
– –
-18,000
Closed -$879K
DVAX
142
DELISTED
Dynavax Technologies
DVAX
– –
-91,800
Closed -$1.4M
CYTO
143
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-24
Closed -$151K
BLCM
144
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-9,002
Closed -$664K
CLVS
145
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-17,250
Closed -$784K
MDCO
146
DELISTED
Medicines Co
MDCO
– –
-17,050
Closed -$626K
AAC
147
DELISTED
AAC Holdings
AAC
– –
-39,000
Closed -$365K
COTV
148
DELISTED
Cotiviti Holdings, Inc.
COTV
– –
-24,774
Closed -$1.09M
FMI
149
DELISTED
Foundation Medicine, Inc.
FMI
– –
-8,357
Closed -$1.14M
2 3 4 5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2018 Portfolio in Review

As of Q3 2018, Bellevue Group held 149 positions worth $1.58B, up 34% from $1.17B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $220M of net new capital in Q3 2018, opening 11 new positions and adding to 79 existing holdings. Its largest new stake was Pacific Biosciences: 2,575,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was DexCom, an estimated $24.7M trimmed.

  • Bellevue Group's largest Q3 2018 buy was Pacific Biosciences: 2,575,000 shares worth $13.9M.
  • Bellevue Group added most to Abbott in Q3 2018, an estimated $13M increase.
  • Bellevue Group's biggest Q3 2018 reduction was DexCom, cutting an estimated $24.7M.
  • Bellevue Group fully exited Bausch Health in Q3 2018, selling an estimated $3.02M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.58B portfolio in Q3 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q3 2018.
  • Bellevue Group's portfolio value rose 34% quarter-over-quarter to $1.58B.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.